Colon Cancer in Elderly Patients: What is the Best Treatment?

• Lubiz J , CaiL, KramarowEet al.: Health, life expectancy and health care spendine among the elderly. N. Engl. J. Med.349, 1048–1055(2003).
   PubMed Web of Science ®Google Scholar
• Jemal A , SiegelR, WardEet al.: Cancer statistics, 2008. CA Cancer J. Clin.58, 71–96(2008).
   PubMed Web of Science ®Google Scholar
• Jessup JM , McGinnisLS, SteeleGD Jr et al.: The National Cancer Data Base: report on CC. Cancer78, 918–926(1996).
   PubMed Web of Science ®Google Scholar
• De Rijke JM , SchoutenLJ, SchoutenHCet al.: Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann. Oncol.7, 677–685(1998).
   Web of Science ®Google Scholar
• Arveux I , BoutronMC, El Mrini T et al.: Colon cancer in the elderly: evidence for major improvements in health care and survival. Br. J. Cancer76, 963–967(1997).
   PubMed Web of Science ®Google Scholar
• Fitzgerald SD , LongoWE, DanielGLet al.: Advanced colorectal neoplasia in the high-risk elderly patient: is surgical resection justified? Dis. Colon Rectum36, 161–166(1993).
   PubMed Web of Science ®Google Scholar
• Irvin TT : Prognosis of colorectal cancer in the elderly. Br. J. Surg.75, 419–421(1998).
   Google Scholar
• Arnaud JP , SchloegelM, OllierJCet al.: Colorectal cancer in patients over 80 years of age. Dis. Colon Rectum34, 896–898(1991).
   PubMed Web of Science ®Google Scholar
• Whittle J , SteinbergEP, AndersonGFet al.: Results of colectomy in elderly patients with CC, based on Medicare claims data (see comments). Am. J. Surg.163, 572–576(1992).
   PubMed Web of Science ®Google Scholar
• Fong Y , KemenyN, PatyPet al.: Treatment of colorectal cancer: hepatic metastasis. Semin. Surg. Oncol.12, 219–252(1996).
   PubMed Web of Science ®Google Scholar
• Trimble EL , CarterCL, CainDet al.: Representation of older patients in cancer treatment trials. Cancer74, 2208–2214(1994).
   PubMed Web of Science ®Google Scholar
• Tekkis PO , PolonieckiJD, ThompsonMRet al.: ACPGBI Colorectal cancer study 2002 – part A: unadjusted outcomes. (b) Tekkis PP, Poloniecki JD, Thompson MR, Stamatakais JD: ACPGBI Colorectal study 2002 – part B: risk adjusted outcomes. The Association of ColoProctology of Great Britain and Ireland Colorectal Cancer Model. June (2003).
   Google Scholar
• Audisio RA , VeronesiP, FerrarioLet al.: Elective surgery for gastrointestinal tumours in the elderly. Ann. Oncol.8, 317–326(1997).
   PubMed Web of Science ®Google Scholar
• Capra E , ScintuF, ZorcoLet al.: Surgical treatment of colorectal cancer in patients over 80 years. Short and long term results. Minerva Chir.58, 515–522(2003).
   PubMedGoogle Scholar
• Koperna T , KisserM, SchulzF: Emergency surgery for colon cancer in the aged.Arch. Surg.132, 1032–1037(1997).
   PubMedGoogle Scholar
• Ficorella C , CannitaK, RicevutoE: The adjuvant therapy of colonic carcinoma in old age.Minerva Med.90, 232–233(1999).
   PubMedGoogle Scholar
• Brand MI , SaclaridesTJ, DobsonHDet al.: Liver resection for colorectal cancer: liver metastases in the aged. Am. Surg.66, 412–415(2000).
   PubMed Web of Science ®Google Scholar
• Audisio RA , CazzanigaM, VeronesiPet al.: Elective surgery for colorectal cancer in the aged; a clinico-economic evaluation. Br. J. Cancer76, 382–384(1997).
   PubMed Web of Science ®Google Scholar
• Patankar SK , LarachSW, FerraraAet al.: Prospective comparison of laparoscopic vs open resections for colorectal adenocarcinoma over a ten year period. Dis. Colon Rectum46, 601–611(2003).
   PubMed Web of Science ®Google Scholar
• Fleshman J , SargentDJ, GreenEet al.: Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST study group trial. Ann. Surg.246(4), 655–62(2007).
   PubMed Web of Science ®Google Scholar
• Adjuvant therapy for patients with colon and rectal cancer. National Institutes of Health. Conn. Med.54(10), 573–581(1990).
   PubMedGoogle Scholar
• Potosky AL , HarlanLC, KaplanRSet al.: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J. Clin. Oncol.20, 1192–1202(2002).
   PubMed Web of Science ®Google Scholar
• Schrag D , CramerLD, BachPBet al.: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J. Natl Cancer Inst.93, 850–857(2001).
   PubMed Web of Science ®Google Scholar
• Schrag D , Rifas-ShimanS, SaltzLet al.: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J. Clin. Oncol.20, 3999–4005(2002.)
   PubMed Web of Science ®Google Scholar
• Ayanian JZ , ZaslavskyAM, FuchsCSet al.: Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J. Clin. Oncol.21, 1293–1300(2003).
   PubMed Web of Science ®Google Scholar
• Sundararajan V , GrannVR, JacobsonJSet al.: Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer7, 213–218(2001).
   Web of Science ®Google Scholar
• Neugut AI , FleischauerAT, SundararajanVet al.: Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J. Clin. Oncol.20, 2643–2650(2002).
   PubMed Web of Science ®Google Scholar
• Cronin DP , HarlanLC, PotoskyALet al.: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am. J. Gastroenterol.101, 2308–2318(2006).
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics: Health, United States, 2005 with Chartbook on Trends in the Health of Americans. Hyattsville, MD, USA, National Center for Health Statistics (2005).
   Google Scholar
• Sargent DJ , WieandHS, BenedettiJet al.: Disease-free survival vs. overall survival as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. J. Clin. Oncol.22, 246s (2004).
   Web of Science ®Google Scholar
• Gross CP , McAvayGJ, KrumholzHMet al.: The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: Implications for screening. Ann. Intern. Med.145, 646–653(2006).
   PubMed Web of Science ®Google Scholar
• Sargent DJ , GoldbergRM, JacobsonSDet al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med.345, 1091–1097(2001).
   PubMed Web of Science ®Google Scholar
• Gill S , LoprinziCL, SargentDJet al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol.22, 1797–1806(2004).
   PubMed Web of Science ®Google Scholar
• D‘Andre S , SargentDJ, ChaSSet al.: 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a North Central Cancer Treatment Group study. Clin. Colorectal Cancer4, 325–331(2005).
   PubMedGoogle Scholar
• Iwashyna TJ , LamontEB: Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.J. Clin. Oncol.20, 3992–3998(2002).
   PubMed Web of Science ®Google Scholar
• Fata F , MirzaA, CraigGet al.: Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer94, 1931–1938(2002).
   PubMed Web of Science ®Google Scholar
• Sundararajan V , MitraN, JacobsonJSet al.: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann. Intern. Med.136, 349–357(2002).
   PubMed Web of Science ®Google Scholar
• André T , BoniC, Mounedji-BoudiafLet al.: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350(23), 2343–23451(2004).
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio F , BurrisH 3rd, Douillard JY et al.: Safety of capecitabine (X) compared to fluorouracil/leucovorin (5–5FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). J. Clin. Oncol.22(14 Suppl.), 258s (2004).
   Google Scholar
• Twelves C , WongA, NowackiMPet al.: Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352, 2696–2704(2005).
   PubMed Web of Science ®Google Scholar
• Neugut AI , MatasarM, WangXet al.: Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J. Clin. Oncol.24, 2368–2375(2006).
   PubMed Web of Science ®Google Scholar
• Dobie SA , BaldwinLM, DominitzJAet al.: Completion of therapy by Medicare patients with stage III colon cancer. J. Natl Cancer Inst.98, 610–619(2006).
   PubMedGoogle Scholar
• Chau I , NormanAR, CunninghamDet al.: A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann. Oncol.16, 549–557(2005).
   PubMed Web of Science ®Google Scholar
• Simmonds PC : Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis – Colorectal Cancer Collaborative Group.Br. Med. J.321, 531–535(2003).
   Google Scholar
• Folprecht G , CunninghamD, RossPet al.: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann. Oncol.15, 1330–1338(2004).
   PubMed Web of Science ®Google Scholar
• Mattioli R , LippeP, RecchiaFet al.: Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res.21, 489–492(2001).
   PubMed Web of Science ®Google Scholar
• Daniele B , RosatiG, TambaroRet al.: First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a Phase II study. J. Clin. Gastroenterol.36, 228–233(2003).
   PubMed Web of Science ®Google Scholar
• Escudero P , LlosaFet al.: Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J. Clin. Oncol.23, 3104–3111(2005).
   PubMedGoogle Scholar
• Cripps M , VincentM, JonkerDet al.: Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer. J. Clin. Oncol.23, 265s (2005).
   Google Scholar
• Popa E , LuoW, HochsterHet al.: A Phase II study of orzel (UFT + leucovorin) in elderly (≥75 years old) patients with colorectal cancer: results of ECOG 1299. J. Clin. Oncol.23, 273s (2005).
   Google Scholar
• Goldberg RM , Tabah-FischI, BleibergHet al.: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol.24, 4085–4091(2006).
   PubMed Web of Science ®Google Scholar
• Mattioli R , MassacesiC, RecchiaFet al.: High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann. Oncol.16, 1147–1151(2005).
   PubMed Web of Science ®Google Scholar
• Oh D -Y, Kim Y-J, Han S-W et al.: Efficacy of reduced intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J. Clin. Oncol.23, 300s (2005).
   Web of Science ®Google Scholar
• Figer A , PerezN, CarolaEet al.: 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer. J. Clin. Oncol.22, 263 (2004).
   Google Scholar
• Feliu J , SaludA, EscuderoPet al.: XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br. J. Cancer94, 969–975(2006).
   PubMed Web of Science ®Google Scholar
• Comella P , NataleD, FarrisAet al.: Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer104, 282–289(2005).
   PubMed Web of Science ®Google Scholar
• Comandone A , PochettinoP, BergnoloPet al.: Capecitabine and oxaliplatin: a Phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. J. Clin. Oncol.23, 291s (2005).
   Google Scholar
• Twelves CJ , ButtsCA, CassidyJet al.: Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large Phase II study. Clin. Colorectal Cancer5, 101–107(2005).
   PubMedGoogle Scholar
• Folprecht G , RougierP, SaltzLet al.: Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer : metanalysis of four trials investigating 5-FU and irinotecan. J. Clin. Oncol.24, 165s (2006).
   Web of Science ®Google Scholar
• Fuchs C , MooreMR, HarkerGet al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol.21, 807–814(2003).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML , MeropolNJ, PoplinEAet al.: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol.19, 3801–3807(2001).
   PubMed Web of Science ®Google Scholar
• Sastre J , MarcuelloE, MasuttiBet al.: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J. Clin. Oncol.23, 3545–3551(2005).
   PubMed Web of Science ®Google Scholar
• Souglakos J , PallisA, KakolyrisSet al.: Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a Phase II trial. Oncology69, 384–390(2005).
   PubMed Web of Science ®Google Scholar
• Kohne CH , van Cutsem E, Wils J et al.: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol.23, 4856–4865(2005).
   PubMed Web of Science ®Google Scholar
• Saltz LB , CoxJV, BlankeCet al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N. Engl. J. Med.343, 905–914(2000).
   PubMed Web of Science ®Google Scholar
• Fiorentini G , DenticoP, CantoreMet al.: Capecitabine plus irinotecan as second-line treatment for metastatic colorectal cancer in elderly patients: feasibility and safety results from a Phase II study. J. Clin. Oncol.23, 289s (2005).
   Google Scholar
• Berry S , CunninghamD, MichaelMet al.: Preliminary safety of bevacizumab with first-line FOLFOX, CAPOCX, FOLFIRI and capecitabine for mCC – first B.E.A. Trial. J. Clin. Oncol.24, 154s (2006).
   Web of Science ®Google Scholar
• Hedrick E , KozloffM, HainsworthJet al.: Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRITE). J. Clin. Oncol.24, 155s (2006).
   Web of Science ®Google Scholar
• Pasetto L , FalciC, SinigagliaGet al.: How many colorectal cancer patients older than 70 years may be safely treated with bevacizumab. J. Clin. Oncol.24, 623s (2006).
   Google Scholar

Website

• Genentech (2006): Avastin® full prescribing information. www.gene.com/gene/products/information/oncology/avastin/insert.jsp
   Google Scholar